Skip to Content

What is the difference between Fulphila and Neulasta?

Medically reviewed by Last updated on Sep 19, 2019.

Official Answer


Fulphila (pegfilgrastim-jmbd), is a biosimilar to Neulasta (pegfilgrastim).

A biosimilar is a biological product that is highly similar to a biologic already approved by the FDA (known as the reference product) and has no clinically meaningful differences in terms of safety, purity and potency from the reference product. Biosimilars can provide cost effective treatment options to already approved biologics.

Fulphila and Neulasta are both used in cancer patients to boost the production of infection-fighting white blood cells and to help prevent neutropenia caused by chemotherapy.

More information: What Are Biosimilars? Top Facts You May Not Know

Related Medical Questions

Drug Information

Related Support Groups